WO2006029719A3 - Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4) - Google Patents

Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4) Download PDF

Info

Publication number
WO2006029719A3
WO2006029719A3 PCT/EP2005/009412 EP2005009412W WO2006029719A3 WO 2006029719 A3 WO2006029719 A3 WO 2006029719A3 EP 2005009412 W EP2005009412 W EP 2005009412W WO 2006029719 A3 WO2006029719 A3 WO 2006029719A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
nr1h4
therapeutics
diagnostics
group
Prior art date
Application number
PCT/EP2005/009412
Other languages
French (fr)
Other versions
WO2006029719A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006029719A2 publication Critical patent/WO2006029719A2/en
Publication of WO2006029719A3 publication Critical patent/WO2006029719A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Abstract

The invention provides a human NR1H4 which is associated with the cardiovascular diseases, infections, respiratory diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, reproduction diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, respiratory diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, reproduction diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NR1H4 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/009412 2004-09-14 2005-09-01 Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4) WO2006029719A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04021790 2004-09-14
EP04021790.3 2004-09-14

Publications (2)

Publication Number Publication Date
WO2006029719A2 WO2006029719A2 (en) 2006-03-23
WO2006029719A3 true WO2006029719A3 (en) 2006-06-22

Family

ID=35431598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009412 WO2006029719A2 (en) 2004-09-14 2005-09-01 Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4)

Country Status (1)

Country Link
WO (1) WO2006029719A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1285914A1 (en) * 2001-08-13 2003-02-26 LION Bioscience AG Nr1h4 nuclear receptor binding compounds
WO2003015777A1 (en) * 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1285914A1 (en) * 2001-08-13 2003-02-26 LION Bioscience AG Nr1h4 nuclear receptor binding compounds
WO2003015777A1 (en) * 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BISHOP-BAILEY DAVID ET AL: "Expression and activation of the farnesoid X receptor in the vasculature.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 10, 9 March 2004 (2004-03-09), pages 3668 - 3673, XP002358294, ISSN: 0027-8424 *
MALONEYPRETAL: "Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 16, 10 August 2000 (2000-08-10), pages 2971 - 2974, XP002186187, ISSN: 0022-2623 *
URIZAR NANCY L ET AL: "A natural product that lowers cholesterol as an antagonist ligand for FXR.", SCIENCE (WASHINGTON D C), vol. 296, no. 5573, 31 May 2002 (2002-05-31), pages 1703 - 1706, XP002358293, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
WO2006029719A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2006029719A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2006005460A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 2, group e, member 1 (nr2e1)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2006037495A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 3, group c, member 2 (nr3c2)
WO2006010515A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a)
WO2005114205A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group b, member 2 (nr1b2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase